EASL Podcasts

This episode explores psychohepatology, examining the gut–liver–brain axis and the bidirectional links between liver disease and mental health. Discussion covers addiction biology, the impact of trauma and post-traumatic stress disorder (PTSD) on alcohol use, and the high prevalence of depression and anxiety in cirrhosis, highlighting integrated approaches to liver and mental health care. Host: Mads Israelsen (Odense University Hospital) Guests: Nicola Kalk (South London and Maudsley N...

This EASL Deep Dive explores key updates from the EASL Clinical Practice Guidelines on hepatocellular carcinoma (HCC), with a practical focus on diagnosis and treatment selection. Experts will discuss evolving imaging and diagnostic criteria, patient selection for surgery and locoregional therapies, and how to adapt management according to response to systemic treatment. The session will also highlight the growing importance of multidisciplinary, individualised care across the HCC treatment p...

This episode of Talk Liver to Me explores the practical use of resmetirom and semaglutide in MASH, based on the 2026 EASL–EASD–EASO Guidance. Experts discuss who may benefit from treatment, when to initiate therapy, and how to monitor response and efficacy in clinical practice. Host: Debbie Shawcross (EASL) Guests: Andreea Ciudin (EASO), Amalia Gastaldelli (EASD), Frank Tacke (EASL) This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-18 ...

Liver disease represents a major and under-recognised public health challenge across Africa, driven by a complex interplay of viral hepatitis, rising metabolic dysfunction-associated steatotic liver disease, and a high burden of hepatocellular carcinoma (HCC). Despite this, awareness, surveillance, and access to care remain limited. In this podcast, we explore the evolving epidemiology of liver disease across the continent, highlighting key drivers, regional variations, and gaps in diagnosis ...

This webinar explores the role of genetic testing in diagnosing Progressive Familial Intrahepatic Cholestasis (PFIC). Attendees will review key test types, understand the principles behind modern genomic technologies, and learn how to position these tests in the diagnostic approach of a person with a suspicion of PFIC and how to navigate common challenges in interpreting genetic results. The session will also highlight emerging trends shaping the future of genetic diagnostics in hepatology.&n...

Acute liver failure (ALF) is a rare but life-threatening condition requiring rapid recognition and decisive management. Early decisions around investigation, escalation, and referral can significantly impact outcomes. Despite advances in care, variation in practice and avoidable pitfalls remain common. In this podcast, we take a practical, case-based approach to the key “dos and don’ts” in ALF management, focusing on early diagnosis, initial stabilisation, appropriate investigations, and time...

Endohepatology is emerging as a novel approach to liver disease assessment, with the potential to combine EUS-guided liver biopsy, portal pressure measurement, and variceal evaluation within a single session. This “one-stop shop” model could streamline diagnostic pathways and enable integrated, real-time clinical decision-making. However, this innovation comes at a time when hepatology is moving increasingly towards non-invasive testing strategies. Questions therefore remain around its approp...

Early-career researchers and clinician-scientists play a central role in advancing hepatology research and innovation, yet the transition to independence often comes with challenges that extend beyond scientific expertise. Building a research programme, leading teams, securing funding, and developing a sustainable academic career require skills that are rarely addressed during formal training. In this podcast, we explore the realities of early academic leadership, focusing on the practical an...

Hepatitis E is a globally prevalent infection with diverse clinical manifestations, ranging from self-limiting acute hepatitis to chronic infection in immunosuppressed patients. Its presentation and epidemiology vary significantly between regions, influencing diagnostic and management strategies. Despite increasing recognition, uncertainty remains around who to test, when to treat, and how to manage chronic disease effectively. In this podcast, we bring together perspectives from Europe and A...

Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF) are increasingly recognised as manifestations of a shared cardiometabolic disorder. Driven by overlapping risk factors such as obesity and insulin resistance, these conditions frequently coexist and may interact through liver–heart crosstalk. Despite this, they are typically managed separately, with limited disease-specific therapies and suboptimal outcomes. In this podc...

The following objectives will be addressed in this EASL Deep Dive episode: Have a profound knowledge of the pitfalls, limitations and difficulty of interpretation of the different tests of copper metabolism and liver copper assessmentsBe able to establish a diagnostic approach to Wilson’s disease, integrating clinical, laboratory, genetic and imaging toolsHave a good understanding of the different treatment modalities, how to position them in the disease course, how to monitor treatment and w...

Steatotic liver disease (SLD) research relies heavily on preclinical models, yet no single model can fully capture the complexity of human disease. In this episode, we explore the new EASL position paper on preclinical SLD models. From MASLD and MetALD to organoids and precision-cut liver slices, we discuss the strengths, limitations, and translational relevance of today's most widely used models. How do we choose the right model, and are we any closer to finding the perfect one? Based on EAS...

Haemochromatosis remains one of the most common inherited metabolic disorders, yet it is frequently underdiagnosed and inconsistently managed in clinical practice. With widespread use of iron studies and genetic testing, clinicians are increasingly faced with questions around interpretation, penetrance, and clinical significance. In this podcast, we explore current challenges in diagnosis and management, focusing on who should be tested, how to interpret results, and which patients benefit fr...

In this episode, we discuss the first pig-to-human liver xenotransplantation and the breakthroughs behind the revival of xenotransplantation, examining its potential and remaining challenges. We also explore the accelerating field of machine perfusion, clarifying different approaches and reviewing the evidence supporting their role in organ assessment, optimisation, and DCD utilisation. Host: Sarwa Darwish Murad (Erasmus University Rotterdam) Speakers: Jeroen de Jonge (Erasmus University Rott...

Spontaneous bacterial peritonitis (SBP) remains a major complication of cirrhosis - but rising antimicrobial resistance and emerging data are challenging long-standing practices. In this episode, we review current evidence on primary and secondary prophylaxis, resistance patterns, albumin use, and treatment strategies. How should clinicians balance prevention with antimicrobial stewardship? And where might practice need to evolve in 2026? Host: Thomas Marjot (King's College London) Speakers:&...

In this EASL DeepDive webinar, the expert panel presents and explains the key studies behind the latest recommendations included in the EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. Learning Objectives To identify patients at risk for eCCA, and review the current tools and strategies for its surveillance, diagnosis, staging, and classificationTo define the optimal candidates for resection and liver transplantation, and discuss challenges in the surgic...

This episode explores the role of lifestyle in preventing and managing liver disease, including MASLD/MASH. Our experts discuss the impact of diet and physical activity, why lifestyle change can be difficult to start and sustain, and why small, achievable steps can still make a meaningful difference. Host: Cyrielle Caussy Speakers: Kate Hallsworth and Manuel Romero-Gómez This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-07

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, published in the "Journal of Hepatology" in 2025. Learning objectives Understand the updated EASL recommendations for initiating and discontinuing antiviral therapy in chronic hepatitis B, including key differences with other HBV guidelines. Participants will be able to identify treatment indications and make informed decisions about when a...

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of autoimmune hepatitis, published in the "Journal of Hepatology" in 2025. Learning objectives Select induction and maintenance treatment strategies aimed at achieving complete biochemical responseRecognise and manage disease flares, treatment intolerance, and suboptimal response in autoimmune hepatitisUnderstand tailored approaches to autoimmune hepatitis management in s...

Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult. In this DeepDive Webinar, you’ll be guided through the latest advances in hepatocellular carcinoma management, from the rising impact of immunotherapy combinations to evolving approaches in intermediate-stage disease.&...

In this episode our speakers share their immediate impressions and break down the key highlights shaping the management of portal hypertension and advanced liver disease. What has truly changed in practice? Where was consensus reached and where do controversies remain? Tune in for a clear, practical overview of what you need to know from Baveno VIII. Host: Thomas Marjot Speakers: Mattias Mandorfer and Cristina Ripoll This episode is also available on EASL Campus: https://easlcampus.eu/t...

This episode unpacks the updated BCLC guidelines for hepatocellular carcinoma management. Experts discuss the strengths and limitations of the BCLC model in an era of rapidly evolving systemic therapies and personalised care, sharing real-world examples of when the algorithm helps and when clinical practice diverges. Host: Mattias Mandorfer Speakers: Marco Sanduzzi, Lorenza Rimassa This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-05

As deaths from advanced chronic liver disease rise, many patients never receive timely palliative care. In this episode, we explore why early, holistic support is essential in advanced liver disease and HCC, and unpack key recommendations from the new EASL Position Paper to help reduce suffering and improve quality of life. Host: Debbie Shawcross Speakers: Patrizia-Künzler-Heule, Sumita Verma This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-04

This episode explores whether MetALD is a meaningful clinical entity or an unnecessary complication. Experts discuss the overlap between metabolic dysfunction and alcohol use, the challenges of applying the MetALD definition in practice, and its impact on classification, guidelines, drug development, and patient care. Host: Thomas Marjot Speakers: Mary Rinella , Aleksander Krag This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-03

EASL’s Secretary General and Vice Secretary General share an open conversation on the challenges and opportunities for women in hepatology. The episode explores the role of mentorship across career stages and reflects on the journey toward EASL’s first female Secretary General, offering insights on leadership and change in the field. Host: Maja Thiele Speakers: Debbie Shawcross, Ana Lleo This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-02

In collaboration with the Indian National Association for the Study of the Liver (INASL), hepatologists from South Asia and North America/Europe take listeners inside their liver wards to explore how regional context shapes acute liver care. From admission patterns to alcohol use, infections, DILI, nutrition, and access to transplant, the episode highlights key differences and opportunities for shared learning across regions. This episode is also available on EASL Campus: https://easlcampus.e...

This EASL Studio episode brings key insights from the 2025 EASL–AASLD Consensus Conference on Primary Biliary Cholangitis (PBC). Experts explore the use of surrogate endpoints, the challenges in current trial design and regulation, the value of real-world evidence, and how quality-of-life assessment can support future pathways. Moderator: David Jones Speakers: Marco Carbone, Bettina Hansen, and Ana Lleo All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Vide...

How can we protect young adults from steatotic liver disease (SLD)? This episode explores the burden of MASLD, MetALD, and ALD in Europe, the synergistic effects of alcohol and metabolic risk factors, and why the younger population is especially vulnerable. Experts also examine the disparities in risk factors and the role of clinics and policymakers in prevention. Moderator: Shira Zelber Sagi Speakers: Carina Ferreira-Borges (WHO representative) and Zobair Younossi This EASL Studio is support...

What were the key takeaways from this year’s AASLD The Liver Meeting? In this episode, experts unpack the most impactful studies, clinical insights, and emerging trends shaping the future of hepatology. From liver cancer breakthroughs to MASLD, ALD, and beyond. Moderator: Debbie Shawcross Speakers: Saul Karpen, Allison Kwong, Mazen Noureddin All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

For World Antimicrobial Awareness Week 2025 (“Act Now: Protect Our Present, Secure Our Future”), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial resistance. Moderator: Debbie Shawcross Speakers: Rajiv Jalan, Vishal Patel, Jonel Trebicka All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts. This EASL Studio is supported by Alfasigma and Norgine....

Ever wondered what happens to your manuscript after submission? In this episode, the JHEP Reports editorial team takes you behind the scenes: from first triage to reviewer selection, smart moves vs. red flags, and how final decisions are made. The discussion also explores the potential, limitations, and ethical pitfalls. Moderator: Mattias Mandorfer Speakers: Tobias Böttler, Virginia Hernández-Gea, Josep Llovet All EASL Studio Podcasts are available on EASL Campus. Click here to see all...

After years of limited progress, recent trials hint at a changing landscape for primary sclerosing cholangitis (PSC). In this episode, experts review emerging data and explore whether we’re approaching a new era of effective treatment. How should clinicians assess these therapies, and could they shift the current management of PSC? Moderator: Debbie Shawcross Speakers: Cynthia Levy, Stephen Rossi, Michael Trauner All EASL Studio Podcasts are available on EASL Campus. Click here to see all EAS...

This episode questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful. Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes. A thought-provoking look at where terminology meets bedside care. Moderator: T...

This EASL Studio explores the discrepancy between the huge burden of patients hospitalised with, and dying from, alcohol-related liver disease (ALD) or MetALD, versus the same disease’s near non-existence from population data. The panel will discuss whether current classification systems (heavily favoring metabolic causes) misrepresent the true burden of ALD and MetALD, and what clinicians can do to better map the role of alcohol in liver patients. Moderator: Maja Thiele Speakers: Brian Lee, ...

What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025? Moderator: Ahmed Elsharkawy Speakers: Ashley Brown, Tatyana...

In hepatology, effective care goes beyond diagnostics and treatment. This episode explores the crucial questions hepatologists should ask to truly understand their patients’ needs, values, and priorities. By focusing on communication and patient-centred care, our experts highlight how listening carefully can improve adherence, enhance quality of life, and ultimately lead to better outcomes. Moderator: Pierre-Emmanuel Rautou Speakers: Agnès Dumas, Maria Hjorth, José Willemse, Zobair Younossi A...

This first session in a two-part EASL DeepDive series on the 2024 EASL-EASD-EASO MASLD Clinical Practice Guidelines will provide a detailed examination of the recommendations concerning diagnosis, non-invasive assessment, and risk stratification, with a view to supporting evidence-based clinical practice. Learning objectives Have a good understanding of the concept/definition of MASLD within the framework of the new SLD nomenclature, including its contribution to disease progression in other ...

This episode addresses key challenges in vascular complications of liver disease, including the management of portal vein thrombosis (PVT) in patients with and without cirrhosis. Experts will explore controversies surrounding long-term anticoagulation therapy and discuss insights from the CIRROXABAN paper. Additionally, the episode will shed light on the management of splanchnic artery aneurysms, offering valuable guidance for clinical practice. Moderator: Pierre-Emmanuel Rautou; Facult...

In this new edition of the EASL DeepDive, expert faculty guide participants through a focused and forward-looking discussion on key aspects of advanced MASLD, setting the stage for a deeper understanding of evolving clinical challenges and opportunities. This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive. Learning objectives Understand the Pathophysiology: Describe the key pathophysiological mechanisms...

This EASL Studio episode explores state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. Focusing on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment, the discussion will discuss contemporary methods, frequency, and practical implementation in clinical settings to enhance precision medicine approaches. Moderator: Aleksander Krag Faculty: Meena Bansal, Mattias Ekstedt, Arun...

Listen to this EASL Studio episode to explore how artificial intelligence (AI) is transforming healthcare. Discuss its potential to revolutionise medical practice, its limitations, and whether it poses a threat or an opportunity for the future of the medical profession. Moderator: Ahmed Elsharkawy Faculty: Jakob Kather, Sabela Lens, Ashley Spann Related episodes: EASL Studio at EASL Congress 2024 – Exploring new frontiers: The AI liver taskforce initiativeS4E5 – AI for dummiesS2E...

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials. Moderator: Ahmed Elsharkawy Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su Wang This EASL Studio is supported by Aligos Therapeutics, GSK and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics, GSK or Gilead Scien...

Listen to this EASL Studio episode for insights on the new MASLD guidelines and their practical application. Hear from experts on navigating the nomenclature change, implementing guidelines in clinical workflows, and fostering behavioral change to improve patient outcomes across the care team. Moderator: Sven Francque Faculty: Marta Cervera, Elena George, Shelley Keating This programme is part of the EASL Guidelines Implementation Programme on MASLD supported by Boehringer Ingelheim and...

Listen to this episode for a curated overview of landmark studies and breakthrough data presented at EASL Congress 2025, with expert insights on their clinical relevance and impact on the future of hepatology. Moderator: Thomas Berg Faculty: Hannes Hagström, Verena Keitel, Raj Mookerjee All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

Most liver diseases are diagnosed when it’s already too late. This episode explores the pros and cons of early screening, the gaps in current strategies, and how projects like LIVERAiM are aiming to change the game. Moderator: Ahmed Elsharkawy Faculty: Pere Ginès, Ian Rowe, Maja Thiele All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio episode cuts through the noise to explore alcohol’s true impact on health and society, spotlighting patient stories, public misconceptions, and bold policy solutions from across Europe. Moderator: David Barret (Internal Communications and Multimedia Manager, WHO Regional Office for Europe) Faculty: Carina Ferreira-Borges (Regional Advisor for Alcohol, Illicit drugs and Prison health, WHO Regional Office for Europe), Aleksander Krag (EASL Secretary General), Hazel Martin (BBC ...

What happens when hepatologists and interventional radiologists join forces? This episode discusses the power of collaboration – shared guidelines, joint training, and multidisciplinary care – to improve outcomes in complex liver disease. Moderator: Sven Francque Faculty: Irene Bargellini, Virginia Hernández-Gea, Max Seidensticker All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts.

In this fifth edition of the EASL DeepDive, join Christophe Bureau, Virginia Hernandez-Gea, Marika Rudler, and Manhal Izzy to gain expert insight into the selection, management, and outcomes of patients undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures. This EASL DeepDive webinar is supported by W. L. Gore & Associates. W. L. Gore & Associates has had no input into the content of this EASL DeepDive. Learning objectives Understand the criteria for selecting app...

This EASL Studio episode discusses cutting-edge approaches for managing bleeding varices. Explore the evolution of endoscopic therapies, the role of interventional radiology, and decision-making for high-risk gastric varices. Gain insights into EUS-guided portal pressure assessment and its impact on tailoring treatment strategies. Moderator: Debbie Shawcross Faculty: Wim Laleman, David Patch Related episode S6E14: Endohepatology: The endoscopic liver gold rushAll EASL Studio Podcasts are avai...

In this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency. Learning objectives: Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcoholGet a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approachLearn more a...